2024-10-12 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

This report analyzes Pfizer Inc. (PFE), a pharmaceutical company that develops and markets a wide range of medicines and vaccines. 

### 1. Performance Analysis:

* **Cumulative Return:** PFE's cumulative return is -11.35%, while the S&P 500 (VOO) has returned 134.11%. This places PFE significantly underperforming the market.
* **Relative Deviation:** The current deviation is -145.46, which translates to a relative deviation of 0.63.  This means PFE is lagging behind the market's performance significantly.

### 2. Recent Price Movement:

* **Closing Price:** $29.37
* **5-day Moving Average:** $29.30
* **20-day Moving Average:** $29.24
* **60-day Moving Average:** $29.28

The stock price is slightly above its moving averages, suggesting a potential upward trend.

### 3. Technical Indicators:

* **RSI:** 49.43 - This indicates the stock is currently neither overbought nor oversold.
* **PPO:** 0.21 - This suggests a slightly positive momentum in the stock price.
* **Delta_Previous_Relative_Divergence:** -3.44 - The negative value suggests a recent short-term downward trend in the relative price movement.
* **Expected Return:** 0.0% - This indicates no expected return, suggesting a potential underperformance compared to the S&P 500 (VOO) in the next 5 years.

### 4. Recent Earnings and Outlook:

**Earnings Data:**

| Date       | EPS   | Estimated EPS |
|------------|-------|---------------|
| 2024-07-30 | 0.6   | 0.458         |
| 2024-05-01 | 0.82  | 0.516         |
| 2024-01-30 | 0.1   | -0.19          |
| 2023-10-31 | -0.17 | -0.32          |
| 2023-08-01 | 0.67  | 0.56          |

The most recent earnings report for 2024-07-30 indicates that Pfizer exceeded analysts' expectations, achieving an EPS of 0.6, surpassing the estimated 0.458. This positive surprise could indicate potential growth opportunities for the company.

### 5. News and Recent Issues:

Recent market outlook suggests PFE is facing headwinds due to declining COVID-19 vaccine revenue and potential generic competition for its blockbuster drug, Paxlovid.  Analysts are divided on the company's future prospects. Some anticipate continued growth in its core pharmaceutical businesses, while others are concerned about the potential decline in revenue from its COVID-19 products.

### 6. Comprehensive Analysis:

Pfizer is currently underperforming the market significantly, lagging behind the S&P 500. While the recent earnings report showed a positive surprise, the long-term outlook remains uncertain due to declining COVID-19 vaccine revenue and potential generic competition. 

Technical indicators suggest a neutral market sentiment, with no significant signals for immediate buy or sell decisions. The expected return is 0.0%, suggesting potential underperformance compared to the S&P 500.  

Investors should closely monitor Pfizer's long-term growth strategies, including its focus on developing new drugs and therapies, to assess the company's future potential.

### 7.  Disclaimer:

This report provides a general overview of PFE and should not be considered investment advice. Investors should conduct their own due diligence and consult with a qualified financial professional before making any investment decisions. 
